These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 7796291)
1. Computer modeling of prostate cancer treatment. A paradigm for oncologic management? Miles BJ; Kattan MW Surg Oncol Clin N Am; 1995 Apr; 4(2):361-72. PubMed ID: 7796291 [TBL] [Abstract][Full Text] [Related]
2. A novel computer based expert decision making model for prostate cancer disease management. Richman MB; Forman EH; Bayazit Y; Einstein DB; Resnick MI; Stovsky MD J Urol; 2005 Dec; 174(6):2310-8. PubMed ID: 16280831 [TBL] [Abstract][Full Text] [Related]
3. Medical informatics and clinical decision making: the science and the pragmatics. Shortliffe EH Med Decis Making; 1991; 11(4 Suppl):S2-14. PubMed ID: 1837576 [TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life, satisfaction, and economic outcome measures in studies of prostate cancer screening and treatment, 1990-2000. McNaughton-Collins M; Walker-Corkery E; Barry MJ J Natl Cancer Inst Monogr; 2004; (33):78-101. PubMed ID: 15504921 [TBL] [Abstract][Full Text] [Related]
5. Quality of life after therapy for localized prostate cancer. Penson DF Cancer J; 2007; 13(5):318-26. PubMed ID: 17921731 [TBL] [Abstract][Full Text] [Related]
7. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era. Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy]. Adolfsson J Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336 [TBL] [Abstract][Full Text] [Related]
16. Modeling human behaviors and reactions under dangerous environment. Kang J; Wright DK; Qin SF; Zhao Y Biomed Sci Instrum; 2005; 41():265-70. PubMed ID: 15850116 [TBL] [Abstract][Full Text] [Related]
17. A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment. Strigari L; Orlandini LC; Andriani I; d'Angelo A; Stefanacci M; Di Nallo AM; Benassi M Phys Med Biol; 2008 Sep; 53(18):5045-59. PubMed ID: 18723926 [TBL] [Abstract][Full Text] [Related]
18. The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Grover SA; Coupal L; Zowall H; Rajan R; Trachtenberg J; Elhilali M; Chetner M; Goldenberg L CMAJ; 2000 Apr; 162(7):977-83. PubMed ID: 10763395 [TBL] [Abstract][Full Text] [Related]
20. Measurement of quality of life in men with prostate cancer. Albaugh J; Hacker ED Clin J Oncol Nurs; 2008 Feb; 12(1):81-6. PubMed ID: 18258577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]